News | June 06, 2022
Proxygen and Merck collaborates to develop molecular glue degraders
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Dr Jitendra Singh said, the Biotech Park would act as a hub for incubation of new ideas
Manamed, a pioneering Medical Technology development company, has been granted FDA approval on its latest orthopaedic recovery device, ManaSport.
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
The company exports mobile surgery equipment to over 100 countries from Pune
The company also raised Rs 270 crore investment from Temasek in 2019
Subscribe To Our Newsletter & Stay Updated
